We just wrapped our final press conference for #ACC24 ! ✅ A big thank you to discussants Dr. Marc Bonaca MD MPH, Dr. Jennifer Rymer and Kim Guibone DNP, APRN, FACC, DNP, for their excellent remarks to close out the press program.

You have found it! Your source for free CE/CME via Twitter! Each program provides 0.5h credit for #physicians , #pharmacists , and #nurses on topics of interest in the cardiometabolic space. Expert authors! See archived programs (and still earn credit) at cardiometabolic-ce.com.

Predicting amputation in PAD -
Adding patient comorbidity / diabetes improves risk stratification - should WIFI be DM-WIFI? #ACC2024 #ACC24

Major adverse limb events higher in patients with below knee disease - results from the VOYAGER PAD Angiographic Core Lab #ACC2024 #ACC24

Vascular Year in Review #ACC24 #ACC2024 - exciting new studies including colchicine for AAA!

Next stop 🛑 in B309 is Kevin Rogers presenting - Risk of Adverse Events in Peripheral Artery Disease Patients with Below-Knee Disease: An Analysis from the VOYAGER-PAD Catheter-Based Angiographic Core Lab at 8:49 AM ET! 🚂🚃

Connie Hess shows new data from VOYAGER PAD on the efficacy and safety of DAPT after endovascular lower extremity revascularization! #ACC2024 #ACC24

James Januzzi Jr MD Saint Luke's Mid America Heart Institute Mikhail Kosiborod Marc Bonaca MD MPH Javed Butler Ryan J Tedford MD Robert Mentz, MD Anu Lala-Trindade Nosheen Reza, MD Muthu Vaduganathan Alexandre Mebazaa Next up, CONFIRMATION-HF.

Saint Luke's Mid America Heart Institute is proud to announce we randomized first patient in REDEFINE-HF, an international, randomized, placebo-controlled, event-driven trial of finerenone for the treatment hospitalized heart failure patients with HFmrEF/HFpEF.

classic.clinicaltrials.gov/ct2/show/NCT06…

Super excited about the multispecialty faculty (VS, IR, IC, VM) - all passionate about education! Whether you want to set yourself up for success in managing your vascular patients or simply win vascular jeopardy, we are ready for you! Travel stipend for 1st time attendees 😎

Great pleasure to present data from VOYAGER-PAD trial on Fragile patients at #AHA23 . AHAMeetings AHA Peripheral Vascular Disease Council CPC Clinical Research Marc Bonaca MD MPH

A scary map!

#PAD Collaborative
Calling all of you to be a FORCE to fight against the amputation epidemic

#AHA23 #PAD Collaborative #CLTI #Amputationmap AHA Peripheral Vascular Disease Council AHA Science AHAMeetings #structuralracism #ampute #PAD Vascular Disease Mgm VascularMedicine #SVM

In this interview, Marc Bonaca MD MPH discusses an #AHA2023 study examining trends in discordance between LVEF and ICD-10 codes used in heart failure hospitalizations.

hcplive.com/view/study-hig…

#HeartFailure

In REAL-TIMI 63, among patients with first-time STEMI, male sex and markers of cardiometabolic disease, including increased BMI and diabetes, were associated with increased non-culprit non-calcified coronary plaque volume @kmabdlr Brigham and Women's Medicine Residents @marcbonaca @brianbergmark #AHA23

Dr. Marc Bonaca MD MPH's poster Stem Cell Factor Associated With Critical Limb Ischemia in Patients With Peripheral Artery Disease will be presented in Novel and Emerging Risk Markers for Cardiovascular Disease, in 24 hrs in Sci & Tech Hall Zone 3, Board 3229 Robert Giugliano #AHA23

Stem Cell Factor, a novel biomarker inversely associated with CLI/amputation, identified from proteomic discovery from 7,077 patients as part of the BWH-DH Center in the AHA PVD SFRN Marc Bonaca MD MPH @rgiuliano Andrea Bellavia #AHA23

Happening now !
“Amputation epidemic in your backyard”

#PAD #PAD Collaborative #Amputationmap
#AHA23 Josh Beckman Stanislav Henkin Daniella KadianDodov AHA Peripheral Vascular Disease Council Marc Bonaca MD MPH Amy West Pollak MD AHA Science Batool Abuhalimeh Sneha Thomas anacasa

Start #AHA23 on the right foot! Dr. Mario Canonico “Impact of Low-Dose Rivaroxaban Plus Aspirin on Myocardial Infarction in Patients With Peripheral Artery Disease With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD” Zone 1 Science & Tech Hall-10:30 AM

Dr. Connie Hess has a special place in our ❤️ and on the main stage! Go listen to her heartfelt words during the Late-Breaking Science: Hot Topics in Management of Coronary Artery Disease/Acute Coronary Syndrome discussion at 10:45 AM ET. #AHA23

In collaboration with our partners, we’re thrilled to announce the TRANSFORM trial, a cutting-edge study aiming to prove the benefits of personalized care strategies for heart disease. Learn more here: cleerlyhealth.com/press/cleerly-… #CardiacCare